**1146 Epidemiology of paroxysmal atrial fibrillation**

J. Goudevenos, J. Vekalis, V. Lathribou, E. Pappa, A. Papathanasiou, L. Michalis, D. Sideris, Department of Cardiology, University Hospital of Ioannina, 45110 Ioannina, Greece

**Background.** Despite its high prevalence little is known regarding the epidemiology of paroxysmal atrial fibrillation (AF). The aim of the study was to determine the incidence and other epidemiological features of AF.

**Methods.** Over a 4-year period we conducted a prospective, population-based survey of cases of AF in a closed population (150,000 inhabitants). Sources for identification of potential cases were the two general district hospitals which serve the studied population. Only patients who suffered at least one episode of AF (> 7 days duration, with abrupt well defined onset of symptoms) out of hospital were included. Patients with AF complicating acute myocardial infarction, acute pericarditis or acute infection were excluded.

**Results.** We identified 391 patients (236 men-155 women) with AF. The overall annual incidence was 9 cases per 10,000 inhabitants (male: 12/10,000/year vs female: 6/10,000). PAF occurred in younger age in men (mean age 57 ± 16 years) than in women (mean age 64 ± 16 years) <p > 0.001>. The incidence rose with the highest rates of incidence among people 80-89 years (28/10,000 for men, 18/10,000 for women); In the elderly (≥ 70 years) the incidence was similar for both sexes (16/10,000 for men, 15/10,000 for women). 122 (31%) patients had more than one episode (23% before and 8% after enrollment). In 37% of cases no cardiovascular risk factor was identified. This was more common for the population <70 years (45%) compared with the elderly (12%) <p > 0.00005>. Hypertension was the most common risk factor occurring in 21% of the men and in 39% of the women. Other risk factors were: valve disease (14%), coronary artery disease (12%), diabetes (10%), thyrotoxicosis (5%), lung disease (3%), sick sinus and pre-excitation syndrome (2%), 23% reported 2 or more risk factors. Heavy alcohol consumption, insomnia and heavy exertion were preceded in 17% of the cases. In 8% of patients the arrhythmia was self-terminated and in 12% DC shock was required because of drug therapy failure.

**Conclusions.** PAF is a common arrhythmia that rises with age. Occurs more frequently and in lower age in men than in women. Hypertension is the most common among the risk factors. Absence of cardiovascular risk factor is more usual in the population <70 years than the elderly.

**1147 Natural history of acute atrial fibrillation**

Björn Hornestam, Peter Held. Dept. of Medicine, Östra University Hospital, Göteborg, Sweden

Acute atrial fibrillation (AF) is a common arrhythmia with a considerable rate of complications. The natural course during the acute phase is not well described. In the recent DAAF trial 110 female and 129 male patients, with a mean age 66.2 ± 16 years) than in women (mean age 64 ± 16 years) <p > 0.001>. The incidence rose with age with the highest rates of incidence among people 80-89 years (28/10,000 for men, 18/10,000 for women). In the elderly (≥ 70 years) the incidence was similar for both sexes (16/10,000 for men, 15/10,000 for women). 122 (31%) patients had more than one episode (23% before and 8% after enrollment). In 37% of cases no cardiovascular risk factor was identified. This was more common for the population <70 years (45%) compared with the elderly (12%) <p > 0.00005>. Hypertension was the most common risk factor occurring in 21% of the men and in 39% of the women. Other risk factors were: valve disease (14%), coronary artery disease (12%), diabetes (10%), thyrotoxicosis (5%), lung disease (3%), sick sinus and pre-excitation syndrome (2%), 23% reported 2 or more risk factors. Heavy alcohol consumption, insomnia and heavy exertion were preceded in 17% of the cases. In 8% of patients the arrhythmia was self-terminated and in 12% DC shock was required because of drug therapy failure.

**Conclusions.** PAF is a common arrhythmia that rises with age. Occurs more frequently and in lower age in men than in women. Hypertension is the most common among the risk factors. Absence of cardiovascular risk factor is more usual in the population <70 years than the elderly.

**1148 Chronic atrial fibrillation: success rate of serial cardioversion therapy and long-term safety and efficacy of oral anticoagulation**

I.C. Van Gelder, H.J.G.M. Crijns, R.G. Tieleman, J. Brögemann, P.J. De Kam, A.T.M. Gosselin, F.W.A. Verheugt, K.I. Lie, Thoraxcenter, University Hospital Groningen; 1 University Hospital Nijmegen, The Netherlands

The purpose of this study was to determine the long-term success rate of the serial electrical cardioversion (ECV) approach in patients with chronic atrial fibrillation (AF) and to assess the efficacy and safety of oral anticoagulation in these patients.

**Methods.** Patients with chronic (> 24 hours) AF received ≥ 4 weeks anticoagulant therapy (OAC) prior to ECV. No prophylactic antiarrhythmic agent was given after the first ECV. Relapses were managed by repeated ECVs whereas serially antiarrhythmic drugs were instituted. OAC was withdrawn after 4 weeks sinus rhythm.

**Results.** 236 patients were followed for 3.7 ± 1.6 years. Mean age was 63 ± 12 years. Underlying disease was coronary artery disease in 29%, rheumatic disease in 17%, non-rheumatic valvular disease in 16%, hypertension in 17% and 22% had "lone" AF. Median duration of AF was 9 months, left atrial size was 46 ± 8 mm. The actuarial cumulative percentages of patients maintaining sinus rhythm after serial ECV treatment was 42% and 27% after 1 and 4 years, respectively. Multivariate analysis showed that factors which were associated with failure of this approach included: arrhythmia duration > 36 months (risk ratio 5.0, <p > 0.001), pectoralis major involvement (functional class III, risk ratio 1.8, <p > 0.001), and age ≥ 56 years (risk ratio 1.5, <p > 0.038). The anticoagulation level of INR 2.4-4.8 was associated with an incidence of thromboembolism and bleeding complications of 0.2% and 1.5%, respectively.

In conclusion, this study shows that many patients with AF fail to respond to the serial ECV strategy. However, this approach postpones the continuous prophylactic oral treatment and determines the exposure time to the deleterious effects related to AF. In addition, thromboembolic events were infrequent in the patients who were subject to this regimen.

**1149 Effects of intra-venously administered digoxin in acute atrial fibrillation, compared to placebo**

B. Hornestam 1, P. Held 1, T. Carlsson 2, L. Falk 3, B. Karlsson 4, T. Lundström 5, M. Pettersson 6, for the DAAF Study Group. 1 Department of Medicine, Östra University Hospital, Göteborg; 2 Department of Medicine, Varberg Hospital; 3 Department of Medicine, Moerdal Hospital; 4 Department of Medicine, Uddevalla Hospital; 5 Department of Medicine, Skövde Hospital; 6 Department of Medicine, Lidköping Hospital, Sweden

Acute atrial fibrillation (AF) is a common arrhythmia. Although no controlled clinical trial investigating the effects of acute intravenous (i.v) treatment with digoxin has been reported, this treatment is widely used to control heart rate and to regain sinus rhythm.

In a randomized, doubleblind, multicenter trial we compared the effects of i.v administered digoxin with placebo in 239 patients (110 female/129 male, mean age 68.2, range 21-89 years) with atrial fibrillation of maximally 7 days duration (mean duration 22.0 h, range 1.5-174.5 h). 129 patients had their first episode of AF, 110 had recurrent AF. Digoxin was given i.v at times 0, 2 and 6 h after inclusion, in the dose of 0.5 mg (mean 0.46 mg, 0.31 mg and 0.32 mg). The primary end-point was conversion to sinus rhythm. Effects on heart rate were one secondary end-point. The duration of the study was 16 h, from inclusion. The groups were demographically well matched. 117 patients were randomized to digoxin, and 122 to placebo.

There were no significant differences in rate of conversion to sinus rhythm between the groups. Conversion to sinus rhythm occurred earlier in the digoxin treated group compared to placebo, but the difference was not quite statistically significant. The heart rate at 16 h was significantly lower in the digoxin treated group, in patients still remaining in AF.

**Table: Duration of AF, HR at baseline, HR at 16 h in AF, Sinus rhythm, Time to SR**

<table>
<thead>
<tr>
<th>Duration of AF</th>
<th>HR at baseline</th>
<th>HR at 16 h in AF</th>
<th>Sinus rhythm</th>
<th>Time to SR</th>
</tr>
</thead>
<tbody>
<tr>
<td>2 h 6 h 12 h 16 h</td>
<td>n = 122: bpm</td>
<td>n = 122: bpm</td>
<td>n = 122: bpm</td>
<td>n = 122: bpm</td>
</tr>
<tr>
<td>n.s</td>
<td>n.s</td>
<td>n.s</td>
<td>n.s</td>
<td>n.s</td>
</tr>
<tr>
<td>20.7 ± 29.9h</td>
<td>120 ± 23</td>
<td>91 ± 20</td>
<td>60/117</td>
<td>4.7 ± 4.2h</td>
</tr>
<tr>
<td>5.8 ± 4.9h</td>
<td>123 ± 25</td>
<td>56/120</td>
<td>5.8 ± 4.9h</td>
<td>p &lt; 0.0001</td>
</tr>
<tr>
<td>n.s</td>
<td>n.s</td>
<td>n.s</td>
<td>n.s</td>
<td>0.18</td>
</tr>
</tbody>
</table>

Digoxin treated patients experienced significantly bradycardia, but none needed treatment other than observation.

In conclusion intravenously administered digoxin results in a statistically non-significantly earlier conversion to sinus rhythm and a significant decrease in heart rate in patients still in atrial fibrillation, compared to placebo. Digoxin does not differ from placebo in the total conversion to sinus rhythm during 16 hours of treatment and observation.

**Atrial fibrillation** 201